New CRISPR-based map ties every human gene to its function
Jonathan Weissman and collaborators used their single-cell sequencing tool Perturb-seq on every expressed gene in the human genome, linking each to its job in the cell.
Jonathan Weissman and collaborators used their single-cell sequencing tool Perturb-seq on every expressed gene in the human genome, linking each to its job in the cell.
MIT neuroscientists expand CRISPR toolkit with new, compact Cas7-11 enzyme.
K. Lisa Yang Brain-Body Center to investigate the brain’s complex relationship with other body systems.
Family trees of lung cancer cells reveal how cancer evolves from its earliest stages to an aggressive form capable of spreading throughout the body.
Postdoc Digbijay Mahat became a cancer researcher to improve health care in Nepal, but the Covid-19 pandemic exposed additional resource disparities.
MIT senior Daniel Zhang aims to provide hope for young patients and support to young students.
HASTS PhD student Rijul Kochhar tracks changing medical and microbial realities, and examines what they portend for society.
Professors Linda Griffith and Feng Zhang along with Guillermo Ameer ScD ’99, Darrell Gaskin SM ’87, William Hahn, and Vamsi Mootha recognized for contributions to medicine, health care, and public health.
Exploring diversity among bacterial immune systems, McGovern Institute scientists uncovere a programmable system for precisely targeting and modifying RNA.
Researchers find RNA-guided enzymes are more diverse and widespread than previously believed.
Made of components found in the human body, the programmable system is a step toward safer, targeted delivery of gene editing and other molecular therapeutics.
Four times faster than conventional PCR methods, new RADICA approach is highly specific, sensitive, and resistant to inhibitors.
Novel method, developed by McGovern Institute researchers, may lead to safer, more efficient gene therapies.
Kytopen is speeding up both discovery and delivery of engineered cell therapies with its transformative Flowfect platforms.
KSQ Therapeutics uses technology created at MIT to study the role of every human gene in disease biology.